CYCLERION THERAPEUTICS, INC. Payments for Restructuring
CYCLERION THERAPEUTICS, INC. (CYCN) reported Payments for Restructuring of $1.37 million for the 12-month period ending 2023-12-31, per its 10-K/A filed 2025-11-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2025-11-12
- CYCLERION THERAPEUTICS, INC. payments for restructuring for the quarter ending 2023-12-31 was $300.00K.
- CYCLERION THERAPEUTICS, INC. payments for restructuring for the quarter ending 2023-09-30 was $283.00K.
- CYCLERION THERAPEUTICS, INC. payments for restructuring for the quarter ending 2023-06-30 was $123.00K.
- CYCLERION THERAPEUTICS, INC. payments for restructuring for the quarter ending 2023-03-31 was $668.00K.
- CYCLERION THERAPEUTICS, INC. payments for restructuring for fiscal 2023 was $1.37M, a 165.25% increase from fiscal 2022.
- CYCLERION THERAPEUTICS, INC. payments for restructuring for fiscal 2022 was $518.00K.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2023-12-31 | $300.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-12 | $583.00K derived: sum of 2 quarters · filed 2025-11-12 | $706.00K derived: sum of 3 quarters · filed 2025-11-12 | $1.37M 10-K/A · filed 2025-11-12 |
| 2023-09-30 | $283.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $406.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.07M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $791.00K 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $668.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $518.00K 10-K · filed 2023-03-22 | |||
| 2020-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $646.00K derived: sum of 2 quarters · filed 2020-11-05 | $2.14M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $594.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $2.08M 10-Q · filed 2020-08-03 | ||
| 2020-03-31 | $1.49M 10-Q · filed 2020-05-04 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $358.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $358.00K 10-Q · filed 2019-08-12 | ||
| 2019-03-31 | $358.00K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |